The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 9th 2025
Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Ophthalmologists See Promise and Peril, but Lack Familiarity, With Biosimilars
July 19th 2022Until recently, ophthalmologists in the United States have had no experience with biosimilars, despite the availability of biosimilars for bevacizumab, which is commonly used off label for ophthalmic conditions.
Read More
Vaccine Candidate Effective in Preventing Against RSV, Phase 2a Study Finds
July 19th 2022Results from a phase 2a study show that a bivalent prefusion F vaccine was effective against symptomatic respiratory syncytial virus (RSV) infection and viral shedding, with no identified safety concerns.
Read More
Dr Debra Patt Discusses the Paradigm Shift of Treating HER2-Low Breast Cancer
July 19th 2022Previously, patients with low expression of HER2 were categorized as HER2-negative but adding the HER2-low classification creates new opportunities for patients with advanced breast cancer, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Watch
ASRS Posters Review Long-term Visual Outcomes, Treatment Burden of Anti-VEGF Therapies
July 16th 2022Posters presented at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting evaluated the association between long-term visual acuity outcomes and use of anti–vascular endothelial growth factor (VEGF) therapy, as well as patient and caregiver experience with ant-VEGF.
Read More
Identifying Long-term Treatment Patterns of Anti-VEGF for DME and the Ideal Dosing Paradigm
July 16th 2022While anti–vascular endothelial growth factor (VEGF) therapy is the first-line treatment for diabetic macular edema (DME), a majority of patients discontinue therapy after 6 months and there is no consensus on the ideal dosing paradigm.
Read More
Predicting Visual Outcomes and Visual Improvement in Macular Edema Due to CRVO
July 16th 2022A machine learning model was able to predict visual outcomes and showed that the time from diagnosis to first treatment indicates visual improvement in patients with macular edema due to central retinal vein occlusion (CRVO).
Read More
Dr Parisa Emami-Naeni Reviews Remote Retinal Imaging During the Pandemic
July 15th 2022At the beginning of the pandemic, remote retinal imaging declined sharply due to a recommendation to stop nonessential eye care services in the first months of 2020, said Parisa Emami-Naeni, MD, MPH, assistant professor of ophthalmology at University of California, Davis, and vitreoretinal surgeon and uveitis specialist at UC Davis Eye Center.
Watch
Clinical Profile of COVID-19 Infection in Postvaccination Individuals
This article describes the findings of an observational study carried out in India to examine the clinical profile of individuals detected to be COVID-19 positive post vaccination.
Read More
Risk of T2D From Corticosteroid Exposure Associated With Age, Sex, BMI, Steroid Dose
July 15th 2022A recent study characterized the known association between corticosteroid exposure and type 2 diabetes (T2D), finding risk to be associated with treatment- and patient-related characteristics that can inform prescription of treatment with steroids.
Read More